alprazolam has been researched along with Acute Post-Traumatic Stress Disorder in 20 studies
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)
alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Posttraumatic stress disorder (PTSD) and panic disorder (PD) share several clinical features, and theory postulates that phasic arousal is similarly dysregulated in both." | 5.30 | Alprazolam reduces response to loud tones in panic disorder but not in posttraumatic stress disorder. ( Bloch, M; Bonne, O; Peri, T; Shalev, AY, 1998) |
| "Combat veterans with PTSD underwent 6 weeks of VR exposure therapy combined with either d-cycloserine (DCS), alprazolam (ALP), or placebo (PBO)." | 2.82 | Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy. ( Bradley, B; Breazeale, KG; Davis, M; Duncan, E; Gerardi, M; Jovanovic, T; Norrholm, SD; Price, M; Ressler, KJ; Rizzo, A; Rothbaum, BO; Tuerk, PW, 2016) |
| "Symptoms specific to PTSD were not significantly altered." | 2.67 | Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. ( Braun, P; Dasberg, H; Greenberg, D; Lerer, B, 1990) |
| "Posttraumatic stress disorder (PTSD) may develop after exposure to severe stress, such as combat, accidents, assaults, and natural disasters." | 2.38 | New approaches in the pharmacotherapy of posttraumatic stress disorder. ( Hales, RE; Sandberg, DP; Silver, JM, 1990) |
| "Alprazolam was associated with a significant attenuation of the HPA-response, suggesting a possible link between initial HPA-axis response disruption and the subsequent unfavorable outcomes." | 1.35 | Alprazolam treatment immediately after stress exposure interferes with the normal HPA-stress response and increases vulnerability to subsequent stress in an animal model of PTSD. ( Cohen, H; Kaplan, Z; Matar, MA; Zohar, J, 2009) |
| "One patient died of pulmonary edema and subsequent heart failure, but the rest of the patients recovered without any sequelae." | 1.34 | Hemoperfusion in the treatment of acute clozapine intoxication in China. ( Cai, ZJ; He, JL; Li, WB; Ungvari, GS; Xiang, YT, 2007) |
| "Posttraumatic stress disorder (PTSD) and panic disorder (PD) share several clinical features, and theory postulates that phasic arousal is similarly dysregulated in both." | 1.30 | Alprazolam reduces response to loud tones in panic disorder but not in posttraumatic stress disorder. ( Bloch, M; Bonne, O; Peri, T; Shalev, AY, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 7 (35.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rauch, SAM | 1 |
| Koola, C | 1 |
| Post, L | 1 |
| Yasinski, C | 1 |
| Norrholm, SD | 4 |
| Black, K | 1 |
| Rothbaum, BO | 6 |
| Signorelli, MS | 1 |
| Costanzo, MC | 1 |
| Cinconze, M | 1 |
| Concerto, C | 1 |
| Price, M | 4 |
| Jovanovic, T | 3 |
| Gerardi, M | 2 |
| Dunlop, B | 1 |
| Davis, M | 2 |
| Bradley, B | 2 |
| Duncan, EJ | 1 |
| Rizzo, A | 2 |
| Ressler, KJ | 2 |
| Neylan, TC | 1 |
| Maples, JL | 1 |
| Heekin, M | 1 |
| Granoff, AL | 1 |
| Ressler, K | 2 |
| Smith, E | 1 |
| Breazeale, KG | 1 |
| Duncan, E | 1 |
| Tuerk, PW | 1 |
| Matar, MA | 1 |
| Zohar, J | 1 |
| Kaplan, Z | 1 |
| Cohen, H | 1 |
| He, JL | 1 |
| Xiang, YT | 1 |
| Li, WB | 1 |
| Cai, ZJ | 1 |
| Ungvari, GS | 1 |
| Shalev, AY | 2 |
| Bloch, M | 1 |
| Peri, T | 2 |
| Bonne, O | 2 |
| Gelpin, E | 1 |
| Brandes, D | 1 |
| Glod, CA | 1 |
| Silver, JM | 1 |
| Sandberg, DP | 1 |
| Hales, RE | 1 |
| Braun, P | 1 |
| Greenberg, D | 1 |
| Dasberg, H | 1 |
| Lerer, B | 1 |
| Risse, SC | 1 |
| Whitters, A | 1 |
| Burke, J | 1 |
| Chen, S | 1 |
| Scurfield, RM | 1 |
| Raskind, MA | 1 |
| Patterson, JF | 1 |
| Feldmann, TB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Cognitive Enhancer May Facilitate Behavioral Exposure Therapy for Veterans With PTSD[NCT00356278] | Phase 2/Phase 3 | 156 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Early Pharmacological Intervention With Diazepam in the Emergency Room Setting to Prevent Posttraumatic Stress Disorder (PTSD).[NCT01221883] | Phase 4 | 40 participants (Anticipated) | Interventional | 2013-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Scores may range from 0 (no symptoms) to 136 (severe symptoms). The score is based on the first 17 CAPS items administered. (NCT00356278)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| VRE Therapy and D-cycloserine | 85.3 |
| VRE Therapy and Alprazolam | 88 |
| VRE Therapy and Placebo | 82.6 |
Scores may range from 0 (no symptoms) to 136 (severe symptoms). The score is based on the first 17 CAPS items administered. (NCT00356278)
Timeframe: Month 12
| Intervention | units on a scale (Mean) |
|---|---|
| VRE Therapy and D-cycloserine | 48.0 |
| VRE Therapy and Alprazolam | 57.2 |
| VRE Therapy and Placebo | 48.4 |
Scores may range from 0 (no symptoms) to 136 (severe symptoms). The score is based on the first 17 CAPS items administered. (NCT00356278)
Timeframe: Month 3
| Intervention | units on a scale (Mean) |
|---|---|
| VRE Therapy and D-cycloserine | 60.3 |
| VRE Therapy and Alprazolam | 66.8 |
| VRE Therapy and Placebo | 51.5 |
Scores may range from 0 (no symptoms) to 136 (severe symptoms). The score is based on the first 17 CAPS items administered. (NCT00356278)
Timeframe: Month 6
| Intervention | units on a scale (Mean) |
|---|---|
| VRE Therapy and D-cycloserine | 56.0 |
| VRE Therapy and Alprazolam | 63.4 |
| VRE Therapy and Placebo | 46.9 |
Scores may range from 0 (no symptoms) to 136 (severe symptoms). The score is based on the first 17 CAPS items administered. (NCT00356278)
Timeframe: Posttreatment, 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| VRE Therapy and D-cycloserine | 65.9 |
| VRE Therapy and Alprazolam | 69.6 |
| VRE Therapy and Placebo | 63.8 |
PTSD Symptom Scale - Self-Report Version (PSS-SR) is a 17-item self-reported questionnaire to assess symptoms of PTSD. Each of the 17 items describe PTSD symptoms which respondents rate in terms of their frequency or severity using a Likert-type scale ranging from 0 (not at all or only one time) to 3 (almost always or five or more times per week). Ratings on items are summed to create three subscales, including re-experiencing, avoidance, and arousal, as well as a total score (that ranges from 0 to 51). The total score higher than 13 indicates on likelihood of PTSD. (NCT00356278)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| VRE Therapy and D-cycloserine | 32.9 |
| VRE Therapy and Alprazolam | 32.4 |
| VRE Therapy and Placebo | 32.4 |
PTSD Symptom Scale - Self-Report Version (PSS-SR) is a 17-item self-reported questionnaire to assess symptoms of PTSD. Each of the 17 items describe PTSD symptoms which respondents rate in terms of their frequency or severity using a Likert-type scale ranging from 0 (not at all or only one time) to 3 (almost always or five or more times per week). Ratings on items are summed to create three subscales, including re-experiencing, avoidance, and arousal, as well as a total score (that ranges from 0 to 51). The total score higher than 13 indicates on likelihood of PTSD. (NCT00356278)
Timeframe: Month 12
| Intervention | units on a scale (Mean) |
|---|---|
| VRE Therapy and D-cycloserine | 22.6 |
| VRE Therapy and Alprazolam | 24.2 |
| VRE Therapy and Placebo | 21.7 |
PTSD Symptom Scale - Self-Report Version (PSS-SR) is a 17-item self-reported questionnaire to assess symptoms of PTSD. Each of the 17 items describe PTSD symptoms which respondents rate in terms of their frequency or severity using a Likert-type scale ranging from 0 (not at all or only one time) to 3 (almost always or five or more times per week). Ratings on items are summed to create three subscales, including re-experiencing, avoidance, and arousal, as well as a total score (that ranges from 0 to 51). The total score higher than 13 indicates on likelihood of PTSD. (NCT00356278)
Timeframe: Month 3
| Intervention | units on a scale (Mean) |
|---|---|
| VRE Therapy and D-cycloserine | 25.2 |
| VRE Therapy and Alprazolam | 26.1 |
| VRE Therapy and Placebo | 21.4 |
PTSD Symptom Scale - Self-Report Version (PSS-SR) is a 17-item self-reported questionnaire to assess symptoms of PTSD. Each of the 17 items describe PTSD symptoms which respondents rate in terms of their frequency or severity using a Likert-type scale ranging from 0 (not at all or only one time) to 3 (almost always or five or more times per week). Ratings on items are summed to create three subscales, including re-experiencing, avoidance, and arousal, as well as a total score (that ranges from 0 to 51). The total score higher than 13 indicates on likelihood of PTSD. (NCT00356278)
Timeframe: Month 6
| Intervention | units on a scale (Mean) |
|---|---|
| VRE Therapy and D-cycloserine | 24.1 |
| VRE Therapy and Alprazolam | 26.3 |
| VRE Therapy and Placebo | 20.0 |
PTSD Symptom Scale - Self-Report Version (PSS-SR) is a 17-item self-reported questionnaire to assess symptoms of PTSD. Each of the 17 items describe PTSD symptoms which respondents rate in terms of their frequency or severity using a Likert-type scale ranging from 0 (not at all or only one time) to 3 (almost always or five or more times per week). Ratings on items are summed to create three subscales, including re-experiencing, avoidance, and arousal, as well as a total score (that ranges from 0 to 51). The total score higher than 13 indicates on likelihood of PTSD. (NCT00356278)
Timeframe: Posttreatment, 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| VRE Therapy and D-cycloserine | 27.1 |
| VRE Therapy and Alprazolam | 25.6 |
| VRE Therapy and Placebo | 24.2 |
2 reviews available for alprazolam and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Xanax: pros and cons.
Topics: Adult; Alprazolam; Anxiety Disorders; Depressive Disorder; Female; Humans; Panic Disorder; Stress Di | 1992 |
New approaches in the pharmacotherapy of posttraumatic stress disorder.
Topics: Alprazolam; Antidepressive Agents; Carbamazepine; Humans; Lithium; Lithium Carbonate; Monoamine Oxid | 1990 |
7 trials available for alprazolam and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
In session extinction and outcome in Virtual Reality Exposure Therapy for PTSD.
Topics: Adult; Alprazolam; Anxiety; Combined Modality Therapy; Cycloserine; Double-Blind Method; Extinction, | 2018 |
A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.
Topics: Adult; Afghan Campaign 2001-; Alprazolam; Anti-Anxiety Agents; Combined Modality Therapy; Cycloserin | 2014 |
An investigation of outcome expectancies as a predictor of treatment response for combat veterans with PTSD: comparison of clinician, self-report, and biological measures.
Topics: Adult; Alprazolam; Combat Disorders; Combined Modality Therapy; Culture; Cycloserine; Female; Humans | 2015 |
Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy.
Topics: Adult; Alprazolam; Combined Modality Therapy; Cycloserine; Double-Blind Method; Female; Galvanic Ski | 2016 |
Treatment of recent trauma survivors with benzodiazepines: a prospective study.
Topics: Alprazolam; Anxiety Disorders; Arousal; Benzodiazepines; Clonazepam; Follow-Up Studies; Heart Rate; | 1996 |
Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment.
Topics: Adult; Alprazolam; Clinical Trials as Topic; Double-Blind Method; Humans; Middle Aged; Personality I | 1990 |
Alprazolam in the treatment of posttraumatic stress disorder.
Topics: Adult; Alprazolam; Clinical Trials as Topic; Humans; Middle Aged; Outcome and Process Assessment, He | 1987 |
11 other studies available for alprazolam and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
What kind of diagnosis in a case of mobbing: post-traumatic stress disorder or adjustment disorder?
Topics: Adjustment Disorders; Alprazolam; Anti-Anxiety Agents; Crowding; Diagnosis, Differential; Drug Thera | 2013 |
Pharmacologic augmentation of extinction learning during exposure therapy for PTSD.
Topics: Alprazolam; Anti-Anxiety Agents; Cycloserine; Female; Humans; Male; Stress Disorders, Post-Traumatic | 2014 |
The impact of benzodiazepine management in the randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy.
Topics: Alprazolam; Anti-Anxiety Agents; Cycloserine; Female; Humans; Male; Stress Disorders, Post-Traumatic | 2014 |
Response to Granoff.
Topics: Alprazolam; Anti-Anxiety Agents; Cycloserine; Female; Humans; Male; Stress Disorders, Post-Traumatic | 2014 |
Possible negative effects of extinction learning on outcomes for patients receiving exposure therapy.
Topics: Alprazolam; Anti-Anxiety Agents; Cycloserine; Female; Humans; Male; Stress Disorders, Post-Traumatic | 2014 |
Response to Smith.
Topics: Alprazolam; Anti-Anxiety Agents; Cycloserine; Female; Humans; Male; Stress Disorders, Post-Traumatic | 2014 |
Alprazolam treatment immediately after stress exposure interferes with the normal HPA-stress response and increases vulnerability to subsequent stress in an animal model of PTSD.
Topics: Acoustic Stimulation; Alprazolam; Analysis of Variance; Animals; Anti-Anxiety Agents; Behavior, Anim | 2009 |
Hemoperfusion in the treatment of acute clozapine intoxication in China.
Topics: Acute Disease; Adult; Alprazolam; Antipsychotic Agents; China; Clonazepam; Clozapine; Depressive Dis | 2007 |
Alprazolam reduces response to loud tones in panic disorder but not in posttraumatic stress disorder.
Topics: Acoustic Stimulation; Adult; Alprazolam; Arousal; Auditory Perception; Blinking; Diagnosis, Differen | 1998 |
Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder.
Topics: Adult; Alprazolam; Anxiety Disorders; Benzodiazepines; Combat Disorders; Depressive Disorder; Homici | 1990 |
Withdrawal from alprazolam dependency using clonazepam: clinical observations.
Topics: Alprazolam; Ambulatory Care; Clonazepam; Hospitalization; Humans; Male; Middle Aged; Stress Disorder | 1990 |